Enzalutamide in treatment of metastatic castrate resistant metastatic prostate cancer

Simple item page
dc.contributor.authorRichter Igorcs
dc.contributor.authorDvořák Josefcs
dc.date.accessioned2020-06-08T09:46:01Z
dc.date.available02-25-2020en
dc.date.available2020-06-08T09:46:01Z
dc.date.issued2019cs
dc.date.updated05-38-2020en
dc.format.extent4cs
dc.identifier.issn1802-4475cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/156243
dc.language.isoczecs
dc.publisherSolen, s.r.o.cs
dc.publisher.cityPrahacs
dc.relation.ispartofOnkologie solenen
dc.relation.ispartofseries0cs
dc.subjectprostate cancercs
dc.subjectmetastasescs
dc.subjectchemotherapycs
dc.subjecthormonal treatmentcs
dc.subjecttargeted treatmentcs
dc.subjecttreatment toxicitycs
dc.titleEnzalutamide in treatment of metastatic castrate resistant metastatic prostate canceren
dc.titleEnzalutamid v léčbě metastatického kastračně rezistentního karcinomu prostatycs
local.citation.epage157-160cs
local.citation.spage157-160cs
local.identifier.publikace6951
local.relation.issue-cs
Files
Collections